Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant Enterobacterales.

[1]  H. Jacquier,et al.  Inoculum effect of Enterobacterales co-expressing OXA-48 and CTX-M on the susceptibility to ceftazidime/avibactam and meropenem , 2022, European Journal of Clinical Microbiology & Infectious Diseases.

[2]  Anna E. Kasimati,et al.  Epidemiology and in vitro activity of ceftazidime–avibactam, meropenem–vaborbactam, imipenem–relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates , 2021, Infection.

[3]  M. Bassetti,et al.  Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections , 2021, The Journal of antimicrobial chemotherapy.

[4]  B. Fantin,et al.  Expression of CTX-M-15 limits the efficacy of ceftolozane/tazobactam against Escherichia coli in a high inoculum murine peritonitis model. , 2020, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[5]  P. Tamma,et al.  Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children. , 2019, Journal of the Pediatric Infectious Diseases Society.

[6]  Z. Bulman,et al.  Inoculum effect of β-lactam antibiotics. , 2019, The Journal of antimicrobial chemotherapy.

[7]  C. MacDougall,et al.  Recognizing and Overcoming Resistance to New Beta-Lactam/Beta-Lactamase Inhibitor Combinations , 2019, Current Infectious Disease Reports.

[8]  M. Hackel,et al.  In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015. , 2019, International journal of antimicrobial agents.

[9]  M. Souli,et al.  Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens , 2019, Expert opinion on drug metabolism & toxicology.

[10]  J. Kirby,et al.  The Inoculum Effect in the Era of Multidrug Resistance: Minor Differences in Inoculum Have Dramatic Effect on MIC Determination , 2018, Antimicrobial Agents and Chemotherapy.

[11]  M. Ouellette,et al.  Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. , 2017, The Lancet. Infectious diseases.

[12]  D. van Duin,et al.  Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy , 2017, Drugs.

[13]  Ronald N. Jones,et al.  In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. , 2016, The Journal of antimicrobial chemotherapy.

[14]  K. Peck,et al.  Extended-spectrum cephalosporins and the inoculum effect in tests with CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli: potential clinical implications of the revised CLSI interpretive criteria. , 2014, International journal of antimicrobial agents.

[15]  R. López-Rojas,et al.  Inoculum Effect on the Efficacies of Amoxicillin-Clavulanate, Piperacillin-Tazobactam, and Imipenem against Extended-Spectrum β-Lactamase (ESBL)-Producing and Non-ESBL-Producing Escherichia coli in an Experimental Murine Sepsis Model , 2013, Antimicrobial Agents and Chemotherapy.

[16]  D. Burgess,et al.  In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae. , 2004, Diagnostic microbiology and infectious disease.

[17]  F. Soriano,et al.  Relevance of the inoculum effect of antibiotics in the outcome of experimental infections caused by Escherichia coli. , 1990, The Journal of antimicrobial chemotherapy.